A majority of patients in the ablation group, about 63%, were in sinus rhythm at the 60-month follow-up, compared with only 22% (P<0.001) in the group with medically managed AF, “which suggests that maintenance of sinus rhythm is beneficial when achieved without the use of antiarrhythmic drugs,” write the authors, led by Dr Nassir F Marrouche (University of Utah Health, Salt Lake City).
Read the source article here.
Did Advice to Cut Saturated Fats Go Very Wrong? | Medpage Today.
Read this article before you order that triple stack cheeseburger with a side of drug eluding stents.
Or go ahead and order that triple stack cheeseburger and be confused along with the rest of us.
The drug known as TC-5619 failed to show enough evidence of effectiveness against inattentive-predominant ADHD. The Winston-Salem-based company said it will have to reduce its employee count to save money, but it did not announce how many jobs will be affected.
via ADHD drug from Targacept NASDAQ: TRGT disappoints, more layoffs planned – Greensboro – The Business Journal.
While studying the effects of exendin-4 on the pancreas, Dr. Egan and her colleagues found that it also seemed to have beneficial effects on the brain. Specifically, GLP-1 stimulates the growth of neurites (developing neurons) in cell culture, and both GLP-1 and exendin-4 protect mature neurons against cell death. In fact, research increasingly suggests that there may be a link between some neurodegenerative disorders and metabolic dysfunction. The hope is that drugs, such as exendin-4, that enhance metabolic function may also be useful in the treatment of neurologic disease.
Building on these findings, Dr. Egan and others in the NIA Intramural Research Program have tested exendin-4 in cellular and mouse models of several neurodegenerative diseases. The results are promising. For example, using a mouse model of Huntington’s disease, they found that exendin-4 reduces the accumulation of the mutant huntingtin protein, which is implicated in the disease’s onset and progression. The treatment also improved motor function and extended the survival time of the Huntington’s disease mice.
In other studies, investigators found that exendin-4 significantly reduced levels of amyloid beta protein (a hallmark of Alzheimer’s disease) and its precursor molecule in mice models of the disorder. It also proved beneficial in cellular and animal models of another neurodegenerative disorder, amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease.
via National Institute on Aging | The Leader in Aging Research.
Medical News: ACC: Radial Artery Tops Saphenous Vein for CABG – in Meeting Coverage, ACC from MedPage Today
Artery v. Vein in a very interesting study.
“Note that in this study, the use of radial arteries was associated with a lower rate of functional and complete occlusion at five years compared with the use of saphenous veins.”
Medical News: Brain Bleeds Seen With Novel Anti-Clotting Drug – in Cardiovascular, Strokes from MedPage Today
The novel antithrombotic vorapaxar causes intracranial hemorrhage in patients with a history of stroke, Merck announced, explaining why stroke survivors were dropped from trials of the experimental drug.
The Associated Press: Pfizer Alzheimer’s disease drug fails in study
The Boomers are aging and Alzheimer’s incidence is expected to increase. This is disappointing news.